Brief: Upstream Bio Says Primary Endpoint Showed Reduction of -1.95 in Nasal Polyp Score
01/03/2026 14:47
March 1 (Reuters) - Upstream Bio Inc UPB.O: UPSTREAM BIO PRESENTS ADDITIONAL ANALYSES FROM THE PHASE 2 VIBRANT TRIAL OF VEREKITUG IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS AT 2026 AAAAI ANNUAL MEETING UPSTREAM BIO INC - PRIMARY ENDPOINT SHOWED REDUCTION OF -1.95 IN NASAL POLYP SCORE UPSTREAM BIO INC - SECONDARY ENDPOINTS SHOWED REDUCTION IN NASAL CONGESTION SCORE BY -0.96 Source text: ID:nGNX42BmTQ Further company coverage: UPB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Upstream Bio
See all newsUpstream Bio Q2 net loss narrows slightly on lower R&D costs
Upstream Bio Inc expected to post a loss of 76 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Adobe, Caseys General Stores, Oracle
Brief: Upstream Bio To Showcase Additional Efficacy Data From The Phase 2 Vibrant Trial Of Verekitug In Crswnp In Oral Session At Eaaci 2026
Upstream Bio Q1 net loss widens on higher R&D costs